EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Medication Use in Multiple Sclerosis: A Population‐Based Comparison With the General Danish Population

Josefine Windfeld-Mathiasen iD, Henrik Horwitz, Ida M Heerfordt iD, Elisabeth Framke iD, Melinda Magyari

Annals of Clinical and Translational Neurology · 2025-11 · 12 (11) · 2206-2213

DOI: 10.1002/acn3.70155 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 31.07.2025. Verfasst von Josefine Windfeld-Mathiasen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Multiple Sclerosis, Registries, Prescription Drugs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Danish Multiple Sclerosis Society supports the management of the Danish Multiple Sclerosis Registry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the overall use of prescription medications among individuals with multiple sclerosis compared to the general population, with a focus on treatments beyond disease‐modifying therapies.

Methods

We conducted a nationwide, registry‐based study in Denmark. All residents with a diagnosis of multiple sclerosis aged 20–80 years and alive on January 1, 2023, were included and followed for 1 year. Each patient was matched with 10 individuals from the general population based on age, sex, and residence. Prescription data were obtained from the Danish National Prescription Registry and categorized using the Anatomical Therapeutic Chemical classification. Relative risks of medication use were calculated.

Results

A total of 14,491 individuals with multiple sclerosis and 144,910 matched controls were included. Patients with multiple sclerosis had significantly higher use of several therapeutic drug classes, including analgesics (51% vs. 33%; RR: 1.56, 95% CI: 1.52–1.60), agents for constipation (12% vs. 3%; RR: 4.61, 95% CI: 4.36–4.88), spasmolytics, and urological medications. Among specific drugs, the most pronounced differences were observed for modafinil (RR: 323.33, 95% CI: 228.67–457.19), baclofen (RR: 36.51, 95% CI: 33.33–39.99), and fesoterodine (RR: 36.36, 95% CI: 18.66–70.87). In contrast, individuals with multiple sclerosis had lower usage of antidiabetic medications and treatments for chronic obstructive pulmonary disease.

Interpretation

This large, population‐based study reveals extensive use of medications targeting symptoms and comorbidities in individuals with multiple sclerosis. These insights can guide healthcare providers in optimizing patient management, addressing overlooked treatment needs, and improving overall care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisRegistriesPrescription DrugsHumansDenmarkMiddle AgedAdultMaleFemaleAgedYoung AdultAged, 80 and over

Stichwörter der Autor:innen

chronic disease managementdrug utilizationneuroimmunologypharmacoepidemiologypopulation‐based studyprescription patterns

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
  • Department of Geriatric and Palliative Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.

ORCID-Profile: Josefine Windfeld-Mathiasen, Ida M Heerfordt, Elisabeth Framke

Förderung

  • The Danish Multiple Sclerosis Society supports the management of the Danish Multiple Sclerosis Registry

Zitieren

APA

Windfeld-Mathiasen, J., Horwitz, H., Heerfordt, I. M., Framke, E., & Magyari, M. (2025). Medication Use in Multiple Sclerosis: A Population‐Based Comparison With the General Danish Population. Annals of Clinical and Translational Neurology, 12(11), 2206-2213. https://doi.org/10.1002/acn3.70155

Vancouver

Windfeld-Mathiasen J, Horwitz H, Heerfordt IM, Framke E, Magyari M. Medication Use in Multiple Sclerosis: A Population‐Based Comparison With the General Danish Population. Annals of Clinical and Translational Neurology. 2025;12(11):2206-2213. doi:10.1002/acn3.70155

BibTeX
@article{WindfeldMathiasen2025,
  author = {Windfeld-Mathiasen, Josefine and Horwitz, Henrik and Heerfordt, Ida M and Framke, Elisabeth and Magyari, Melinda},
  title = {Medication Use in Multiple Sclerosis: A Population‐Based Comparison With the General Danish Population},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {11},
  pages = {2206--2213},
  doi = {10.1002/acn3.70155}
}
Kostenlos starten →